Bullish & Foolish
Full JUNS fundamentals All 466 on the Survival Watch

JUNSJUPITER NEUROSCIENCES, INC.

Is Jupiter Neurosciences struggling financially?

Yes, by its own account. Jupiter Neurosciences told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

25/100

Fragile

Sector
Biotech/Pharma
Market cap
$4.8M
Source filing
10-Q 14 May 2026
Balance sheet
30 Jun 2026

Cash runway

Not estimable

The latest filings do not carry the cash or cash-flow lines needed to estimate a runway. Publishing a number here would mean inventing one.

What it reported

Cash burned over the last 12 months

$10.6M

What Jupiter Neurosciences told the SEC

…since our inception, and expect to continue to incur significant net losses for the foreseeable future; Our management has concluded that factors raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report; We will require substantial additional capital to…

JUPITER NEUROSCIENCES, INC., Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Cash burn is increasing It is spending 54% more cash per year than it was, so the runway above shortens even if nothing else changes.
  • Debt pressure is material Operating earnings cover only -24.3x the interest bill, so the interest is being met out of cash reserves rather than out of the business.

Other Biotech/Pharma companies that filed the doubt